Tumor Associated Neutrophils as a Biomarker of Chemo-immunotherapy Response in Locally Advanced Non-small Cell Lung Cancer : a Model Based on Neoadjuvant Strategy

Tumor Associated Neutrophils as a Biomarker of Chemo-immunotherapy Response in Locally Advanced Non-small Cell Lung Cancer : a Model Based on Neoadjuvant Strategy

evaluate the predictive value of circulating neutrophil DNA methylation profiles, identified from the ALCINA 2 cohort, on pre-treatment blood samples (T0), for the histological response to neoadjuvant chemo-immunotherapy in patients with resectable non-small cell lung cancer (NSCLC)

Inclusion Criteria:

• Age ≥ 18 years.
• Resectable non-small cell lung cancer (NSCLC), stage IIA to IIIB.
• Lymph node status obtained by Positron Emission Tomoscintigraphy (PET)-scanner, confirmation of lymph node status by optional histological sampling (mediastinoscopy, thoracoscopy, echo-endoscopy).
• No secondary lesions in the cerebrum or extra-cerebrum confirmed on brain MRI, PET scanner +/- injected cerebro-thoraco-abdomino-pelvic scanner.
• Neoadjuvant immunochemotherapy strategy validated by a multidisciplinary consultation meeting (RCP) prior to the start of treatment.
• Lung function compatible with thoracic surgery, patient meets surgical and anesthetic criteria for operability
• Measurable disease according to RECIST criteria version 1.1

Exclusion Criteria:

• Previous systemic treatment for the same CBNPC.
• Diagnosis of another solid tumor within the last 3 years, ‡ excluding non melanoma cutaneous and cervical carcinomas .
• Contraindication to immunotherapy.
• Non-objection to participate in research not collected.
• Patients unable to read and/or write.
• Inability to monitor patient during study period
• Persons unable to express their consent.
• Not affiliated to a social security scheme.
• Persons under court protection.
• Persons participating in another research study with an ongoing exclusion period.
• Pregnant women